We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dermatopathology Specimens Examined by Smartphone-Based Microscopy

By LabMedica International staff writers
Posted on 01 Feb 2016
The incorporation of high-resolution cameras into smartphones has allowed for a variety of medical applications including the use of lens attachments that provide telescopic, macroscopic, and dermatoscopic data. More...


Skin biopsy and the pathologic information that it provides is foundational to the diagnosis and management of dermatologic disease. However, a lack of expertise in dermatopathologic-specimen interpretation in resource-poor areas may impede timely diagnosis and treatment.

Pathologists at the University of Texas Houston Health Science Center (TX, USA) and their collaborators constructed a mobile phone microscope by using a modified method and a 3-mm-diameter sapphire ball lens purchased from Edmund Optics (Barrington, NJ, USA). A total of 1,130 consecutive dermatopathology specimens from mostly community dermatologists were evaluated. The performance characteristics of the smartphone platform were calculated by using conventional light microscopy as the gold standard. The sensitivity and specificity for the diagnosis of melanoma, non-melanoma skin cancers, and other miscellaneous conditions by the phone microscopy platform, as compared with traditional light microscopy, were calculated.

All excisional 101 specimens were excluded because the diagnosis was previously established. Among the 1,021 specimens, 930 (91.1%) were shave biopsies and 91 (8.9%) were punch biopsies from 763 different patients. For 136 basal cell carcinoma cases, the sensitivity and specificity of smartphone microscopy were 95.6% and 98.1%, respectively. The sensitivity and specificity for 94 squamous cell carcinoma cases were 89.4% and 97.3%, respectively. The lowest sensitivity was found in the 15 melanomas at 60%, although the specificity was high at 99.1%. The accuracy of diagnosis of inflammatory conditions and other neoplasms was variable.

The authors concluded that their study demonstrated the potential for a high-performing, low-cost smartphone microscopy system in the diagnosis of cutaneous disease. Studies with larger sample sizes of pigmented lesions, non-melanoma skin cancer (NMSC) subtypes, and dermatologic infections could help improve this modality for point-of-care diagnostics in resource-poor settings. The study was published in the January 2016 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

University of Texas Houston Health Science 
Edmund Optics



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.